糖尿病心血管并发症药物分子靶向递送系统的研究进展

doi:10.12092/j.issn.1009-2501.2026.06.010

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6): 808-820.doi: 10.12092/j.issn.1009-2501.2026.06.010

• “糖尿病心血管并发症的药物进展”专栏 • 上一篇

糖尿病心血管并发症药物分子靶向递送系统的研究进展

刘妍¹^,²^,³(), 秦小江³^,⁴, 魏成杰²^,³, 江雪露²^,³, 郑志发⁵, 彭晓阳⁶, 赵良渊², 施熠炜⁷, 侯晓敏³^,⁸^,*()

1. 山西医科大学药学院，太原 030001，山西
2. 山西医科大学医学科学院，太原 030001，山西
3. 山西医科大学环境暴露血管疾病研究所，太原 030001，山西
4. 山西医科大学公共卫生学院，太原 030001，山西
5. 山西省白求恩医院心胸外科，太原 030032，山西
6. 山西医科大学转化医学研究中心，太原 030001，山西
7. 山西医科大学第一医院呼吸与危重症医学科，太原 030001，山西
8. 山西医科大学基础医学院，太原 030001，山西

收稿日期:2025-07-23 出版日期:2026-06-26 发布日期:2026-07-06
通讯作者: 侯晓敏 E-mail:liuyan584428@163.com;xiaominhou@sxmu.edu.cn
作者简介:刘妍，女，硕士研究生，研究方向：微血管药理学、病理生理学及天然产物的研究。E-mail：liuyan584428@163.com
基金资助:
国家自然科学基金青年项目（82204042）；国家自然科学基金面上项目（82373622）；山西省科技创新人才团队（青年）项目（202304051001038）；山西省科技合作交流专项项目（区域合作项目）（2022040411022）；国家卫生健康委员会尘肺病重点实验室开放课题（NHC202307）；山西省高等教育“百亿工程”科技引导专项（BYJL067）

Research progress on drug molecular targeted delivery systems for cardiovascular complications of diabetes

Yan LIU¹^,²^,³(), Xiaojiang QIN³^,⁴, Chengjie WEI²^,³, Xuelu JIANG²^,³, Zhifa ZHENG⁵, Xiaoyang PENG⁶, Liangyuan ZHAO², Yiwei SHI⁷, Xiaomin HOU³^,⁸^,*()

1. School of Pharmacy, Shanxi Medical University, Taiyuan 030001, Shanxi, China
2. Academy of Medical Sciences, Shanxi Medical University, Taiyuan 030001, Shanxi, China
3. Environmental Exposure Vascular Diseases Institute, Shanxi Medical University, Taiyuan 030001, Shanxi, China
4. School of Public Health, Shanxi Medical University, Taiyuan 030001, Shanxi, China
5. Department of Cardiothoracic Surgery, Bethune Hospital, Shanxi Province, Taiyuan 030032, Shanxi, China
6. Center for Translational Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi, China
7. Department of Respiratory and Critical Care Medicine, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi, China
8. School of Basic Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi, China

Received:2025-07-23 Online:2026-06-26 Published:2026-07-06
Contact: Xiaomin HOU E-mail:liuyan584428@163.com;xiaominhou@sxmu.edu.cn

摘要/Abstract

摘要：

糖尿病（diabetes mellitus，DM）是一种以慢性高血糖为主要特征的代谢性疾病，其病理特征表现为碳水化合物、蛋白质和脂肪代谢紊乱。该疾病可引发大血管病变和微血管病变，进而导致多种严重并发症，如糖尿病神经病变、糖尿病肾病、糖尿病视网膜病变等。心血管并发症是其重要并发症之一，是导致糖尿病患者预后不良、致残率和死亡率升高的关键因素，临床表现涵盖冠心病、糖尿病性心肌病及心血管自主神经病变等多种病理情况。目前临床治疗方案包括血糖调控、血压管理、血脂调节、生活方式干预以及药物治疗等，传统药物递送系统存在显著局限性，具体表现为个体间药效学差异显著、药代动力学参数不理想、长期用药安全性问题突出、靶标特异性不足以及给药途径受限等。随着纳米技术与分子生物学研究的深入，基于高效靶向药物递送系统的治疗策略在糖尿病心血管并发症领域展现出广阔的应用前景，其中高效靶向药物递送系统的研发已成为该领域的重点研究方向。本综述系统梳理了糖尿病心血管并发症靶向治疗的最新研究进展，重点探讨了纳米载体技术、特异性靶向分子设计、智能响应型递送系统以及基因治疗等前沿领域的研究成果，旨在阐明分子靶向递送系统的临床转化价值，并为新型治疗策略的开发提供理论依据和研究思路。

关键词: 糖尿病, 心血管并发症, 分子靶向递送系统, 纳米颗粒

Abstract:

Diabetes mellitus (DM) is a metabolic disorder characterized primarily by chronic hyperglycemia, with pathological features including disorders of carbohydrate, protein, and fat metabolism. This disease can lead to macrovascular and microvascular complications, resulting in various severe complications, such as diabetic neuropathy, diabetic nephropathy, and diabetic retinopathy. Cardiovascular complications are one of the major complications, serving as a key factor contributing to poor prognosis, increased disability rates, and mortality in diabetic patients. Clinical manifestations include coronary heart disease, diabetic cardiomyopathy, and cardiovascular autonomic neuropathy, among other pathological forms. Current clinical treatment options include blood glucose control, blood pressure management, lipid regulation, lifestyle interventions, and drug therapy. Traditional drug delivery systems have significant limitations, including marked interindividual differences in pharmacodynamics, suboptimal pharmacokinetic parameters, prominent long-term safety issues, insufficient target specificity, and limited administration routes. With the advancement of nanotechnology and molecular biology research, treatment strategies based on efficient targeted drug delivery systems have shown great potential in the field of diabetic cardiovascular complications. The development of efficient targeted drug delivery systems has become a key research direction in this field. This review systematically summarizes the latest research progress in targeted therapy for diabetic cardiovascular complications, focusing on the research achievements in cutting-edge fields such as nanocarrier technology, specific targeting molecule design, smart responsive delivery systems, and gene therapy. The aim is to elucidate the clinical translational value of molecular targeted delivery systems and provide theoretical basis and research insights for the development of novel therapeutic strategies.

Key words: diabetes, cardiovascular complications, molecular targeted delivery systems, nanoparticles

中图分类号:

R587.2
R54

刘妍, 秦小江, 魏成杰, 江雪露, 郑志发, 彭晓阳, 赵良渊, 施熠炜, 侯晓敏. 糖尿病心血管并发症药物分子靶向递送系统的研究进展[J]. 中国临床药理学与治疗学, 2026, 31(6): 808-820.

Yan LIU, Xiaojiang QIN, Chengjie WEI, Xuelu JIANG, Zhifa ZHENG, Xiaoyang PENG, Liangyuan ZHAO, Yiwei SHI, Xiaomin HOU. Research progress on drug molecular targeted delivery systems for cardiovascular complications of diabetes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 808-820.

图/表 5

图 1

Fig.1 Mechanisms of functionalized nanoparticles for the treatment of ischemic injury in the heart Passive targeting relies on enhanced permeation and retention (EPR) effects, while active targeting strategies can be achieved by surface modification of specific ligands.

图 2

Fig.2 Metal nanoparticles in the diagnosis and treatment of diabetic cardiovascular diseases

图 3

Fig.3 Exemplary exosome modulation strategies in cardiovascular disease therapy

图 4

Fig.4 Stimuli-responsive nanoparticle drug delivery system triggered by endogenous stimuli Stimuli-responsive nanoparticles encountering endogenous stimuli (low pH, high reactive oxygen species, low oxygen species, and changes in enzyme levels) can achieve targeted drug release at the site of inflammation.

图 5

Fig.5 Targeted delivery of polyethylene glycol (PEG)-modified nanoparticle-attached siRNA in diabetic cardiovascular disease

参考文献 77

1	国家心血管病中心, 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2024概要[J]. 中国循环杂志, 2025, 40 (6): 521- 59. doi: 10.3969/j.issn.1000-3614.2025.06.001
2	Wang W, Qiao J, Zhang L, et al. Prevalence of very high cardiovascular disease risk in patients with type 2 diabetes mellitus: a population-based cross-sectional screening study[J]. Diabetes Obes Metab, 2024, 26 (10): 4251- 4260. doi: 10.1111/dom.15763
3	Kaushal A, Musafir A, Sharma G, et al. Revolutionizing diabetes management through nanotechnology-driven smart systems[J]. Pharmaceutics, 2025, 17 (6): 680.
4	Shi Y, Dong M, Wu Y, et al. An elastase-inhibiting, plaque-targeting and neutrophil-hitchhiking liposome against atherosclerosis[J]. Acta Biomater, 2024, 173, 470- 481. doi: 10.1016/j.actbio.2023.11.020
5	Lobatto ME, Fayad ZA, Silvera S, et al. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis[J]. Mol Pharm, 2010, 7 (6): 2020- 2029. doi: 10.1021/mp100309y
6	Sharifi S, Seyednejad H, Laurent S, et al. Superparamagnetic iron oxide nanoparticles for in vivo molecular and cellular imaging[J]. Contrast Media Mol Imaging, 2015, 10 (5): 329- 355. doi: 10.1002/cmmi.1638
7	Chen X, Tohme M, Park R, et al. Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide[J]. Mol Imaging, 2004, 3 (2): 96- 104. doi: 10.1162/15353500200404109
8	Hu CM, Zhang L, Aryal S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform[J]. Proc Natl Acad Sci U S A, 2011, 108 (27): 10980- 10985. doi: 10.1073/pnas.1106634108
9	George TA, Hsu CC, Meeson A, et al. Nanocarrier-based targeted therapies for myocardial infarction[J]. Pharmaceutics, 2022, 14 (5): 1020.
10	Pala R, Anju VT, Dyavaiah M, et al. Nanoparticle-mediated drug delivery for the treatment of cardiovascular diseases[J]. Int J Nanomedicine, 2020, 15, 3741- 3769. doi: 10.2147/IJN.S250872
11	Shariati L, Esmaeili Y, Rahimmanesh I, et al. Advances in nanobased platforms for cardiovascular diseases: Early diagnosis, imaging, treatment, and tissue engineering [J]. Environ Res, 2023, 238(Pt 1): 116933.
12	Li D, Taylor A, Shi H, et al. Peptide-guided nanoparticle drug delivery for cardiomyocytes[J]. Biology (Basel), 2024, 13 (1): 14. doi: 10.3390/biology13010047
13	Han X, Alameh MG, Xu Y, et al. Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution[J]. Nat Biomed Eng, 2024, 8 (11): 1412- 1424. doi: 10.1038/s41551-024-01267-7
14	Km V, Vijay K, Arvind R. Advancements in herbal-nano formulations: A systematic review[J]. Educ Adm Theory Pract, 2024, 30 (5): 11099- 110109.
15	Prajnamitra RP, Chen HC, Lin CJ, et al. Nanotechnology approaches in tackling cardiovascular diseases[J]. Molecules, 2019, 24 (10): 2017. doi: 10.3390/molecules24102017
16	郑蕊, 屠叶清, 王慧, 等. PLGA作为抗原递送系统的研究进展[J]. 中国生物工程杂志, 2023, 43 (05): 69- 75. doi: 10.13523/j.cb.2211040
17	Chang MY, Yang YJ, Chang CH, et al. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction[J]. J Control Release, 2013, 170 (2): 287- 294. doi: 10.1016/j.jconrel.2013.04.022
18	Catuogno S, Esposito CL, De Franciscis V. Aptamer-mediated targeted delivery of therapeutics: an update[J]. Pharmaceuticals (Basel), 2016, 9 (4): 69. doi: 10.3390/ph9040069
19	Scafa Udriște A, Burdușel AC, Niculescu AG, et al. Metal-based nanoparticles for cardiovascular diseases[J]. Int J Mol Sci, 2024, 25 (2): 1001. doi: 10.3390/ijms25021001
20	Zheng Q, Chen C, Liu Y, et al. Metal nanoparticles: advanced and promising technology in diabetic wound therapy[J]. Int J Nanomedicine, 2024, 19, 965- 992. doi: 10.2147/IJN.S434693
21	Abdelkawi A, Slim A, Zinoune Z, et al. Surface modification of metallic nanoparticles for targeting drugs[J]. Coatings, 2023, 13 (9): 1560.
22	王斐, 陈要臻, 胡兴斌. 抗CD-38和抗CD-47单抗药物对输血相容性检测的干扰与应对策略研究进展[J]. 临床输血与检验, 2023, 25 (4): 559- 564. doi: 10.3969/j.issn.1671-2587.2023.04.026
23	Kaplon H, Crescioli S, Chenoweth A, et al. Antibodies to watch in 2023[J]. MAbs, 2023, 15 (1): 2153410. doi: 10.1080/19420862.2022.2153410
24	Yang Y, Zou H. Research progress on Nrf2 intervention in the treatment of diabetic retinopathy[J]. Front Endocrinol (Lausanne), 2025, 16, 1587231. doi: 10.3389/fendo.2025.1587231
25	Zhang C, Huang J, Yang P, et al. [Irisin Alleviates Inflammatory Injury in Diabetic Cardiomyopathy by Regulating NF-κB Pathway][J]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2023, 54 (3): 545- 551.
26	Ye W, Han K, Xie M, et al. Mitochondrial energy metabolism in diabetic cardiomyopathy: Physiological adaption, pathogenesis, and therapeutic targets[J]. Chin Med J (Engl), 2024, 137 (8): 936- 948. doi: 10.1097/CM9.0000000000003075
27	李思楠, 王玺, 安宇, 等. 植物源生物活性肽的制备、生理活性及作用机制研究进展[J]. 食品工业科技, 2025, 46 (03): 394- 402. doi: 10.13386/j.issn1002-0306.2024010150
28	Ma X, Chuang PH, Tseng YH, et al. Progress in research on animal collagen peptides: preparation, bioactivity, and application[J]. Molecules, 2025, 30 (15): 3520.
29	Kim B, Kim YS, Li W, et al. Ginsenoside Rg5, a potent agonist of Nrf2, inhibits HSV-1 infection-induced neuroinflammation by inhibiting oxidative stress and NF-κB activation[J]. J Ginseng Res, 2024, 48 (4): 384- 394. doi: 10.1016/j.jgr.2024.01.006
30	Zhang J, Ji C, Zhai X, et al. Frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: a bibliometric analysis of 1990-2022[J]. Front Cardiovasc Med, 2023, 10, 1038738. doi: 10.3389/fcvm.2023.1038738
31	Bachheti RK, Worku LA, Gonfa YH, et al. Prevention and treatment of cardiovascular diseases with plant phytochemicals: a review[J]. Evid Based Complement Alternat Med, 2022, 2022, 5741198. doi: 10.1155/2023/9806430
32	Yang P, Liu M, Fan X, et al. Recent advances in natural plant-based treatment of myocardial ischemia-reperfusion injury[J]. Int J Drug Discov Pharmacol, 2023, 2 (1): 1009.
33	周高峰, 肖静, 周佳, 等. 鹿茸多肽预处理通过miR-133a调控TGF-β/Smad信号通路对TBHP诱导心肌H9c2细胞损伤的保护作用[J]. 吉林大学学报(医学版), 2023, 49 (2): 369- 376. doi: 10.13481/j.1671-587X.20230213
34	Soltani D, Azizi B, Rahimi R, et al. Mechanism-based targeting of cardiac arrhythmias by phytochemicals and medicinal herbs: a comprehensive review of preclinical and clinical evidence[J]. Front Cardiovasc Med, 2022, 9, 990063. doi: 10.3389/fcvm.2022.990063
35	Hesari M, Mohammadi P, Khademi F, et al. Current advances in the use of nanophytomedicine therapies for human cardiovascular diseases[J]. Int J Nanomedicine, 2021, 16, 3293- 3315. doi: 10.2147/IJN.S295508
36	Yuan S, Ma T, Zhang YN, et al. Novel drug delivery strategies for antidepressant active ingredients from natural medicinal plants: the state of the art[J]. J Nanobiotechnology, 2023, 21 (1): 391. doi: 10.1186/s12951-023-02159-9
37	Alotaibi BS, Ijaz M, Buabeid M, et al. Therapeutic effects and safe uses of plant-derived polyphenolic compounds in cardiovascular diseases: a review[J]. Drug Des Devel Ther, 2021, 15, 4713- 4732. doi: 10.2147/DDDT.S327238
38	De Abreu RC, Fernandes H, Da Costa Martins PA, et al. Native and bioengineered extracellular vesicles for cardiovascular therapeutics[J]. Nat Rev Cardiol, 2020, 17 (11): 685- 697. doi: 10.1038/s41569-020-0389-5
39	Wang X, Chen Y, Zhao Z, et al. Engineered exosomes with ischemic myocardium-targeting peptide for targeted therapy in myocardial infarction[J]. J Am Heart Assoc, 2018, 7 (15): e008737. doi: 10.1161/JAHA.118.008737
40	Huang L, Wu E, Liao J, et al. Research advances of engineered exosomes as drug delivery carrier[J]. ACS Omega, 2023, 8 (46): 43374- 43387. doi: 10.1021/acsomega.3c04479
41	李旻俊, 彭泽琳, 张良清. 外泌体药物递送载体构建及治疗心血管疾病的研究进展[J]. 中华实用诊断与治疗杂志, 2021, 35 (7): 746- 749. doi: 10.13507/j.issn.1674-3474.2021.07.024
42	Kim H, Yun N, Mun D, et al. Cardiac-specific delivery by cardiac tissue-targeting peptide-expressing exosomes[J]. Biochem Biophys Res Commun, 2018, 499 (4): 803- 808. doi: 10.1016/j.bbrc.2018.03.227
43	Song Y, Zhang C, Zhang J, et al. Localized injection of miRNA-21-enriched extracellular vesicles effectively restores cardiac function after myocardial infarction[J]. Theranostics, 2019, 9 (8): 2346- 2360. doi: 10.7150/thno.29945
44	Okamura A, Yoshioka Y, Saito Y, et al. Can extracellular vesicles as drug delivery systems be a game changer in cardiac disease?[J]. Pharm Res, 2023, 40 (4): 889- 908. doi: 10.1007/s11095-022-03463-z
45	Bu T, Li Z, Hou Y, et al. Exosome-mediated delivery of inflammation-responsive IL-10 mRNA for controlled atherosclerosis treatment[J]. Theranostics, 2021, 11 (20): 9988- 10000. doi: 10.7150/thno.64229
46	Rao D, Huang D, Sang C, et al. Advances in mesenchymal stem cell-derived exosomes as drug delivery vehicles[J]. Front Bioeng Biotechnol, 2021, 9, 797359.
47	Luo T, Zhang Z, Xu J, et al. Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms[J]. Front Bioeng Biotechnol, 2023, 11, 1205751. doi: 10.3389/fbioe.2023.1205751
48	李祥子, 胡平静, 朱振铎, 等. pH响应型纳米药物载体的释药机制及性能研究进展[J]. 无机化学学报, 2018, 34 (8): 1399- 1412. doi: 10.11862/CJIC.2018.195
49	Sung HW, Sonaje K, Liao ZX, et al. pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications[J]. Acc Chem Res, 2012, 45 (4): 619- 629. doi: 10.1021/ar200234q
50	Liu Y, Zeng S, Ji W, et al. Emerging theranostic nanomaterials in diabetes and its complications[J]. Adv Sci (Weinh), 2022, 9 (3): e2102466. doi: 10.1002/advs.202102466
51	Zhang YJ, Zhan X, Wang L, et al. pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model[J]. J Pharm Sci, 2015, 104 (5): 1815- 1824. doi: 10.1002/jps.24407
52	Ma Q, Bian L, Zhao X, et al. Novel glucose-responsive nanoparticles based on p-hydroxyphenethyl anisate and 3-acrylamidophenylboronic acid reduce blood glucose and ameliorate diabetic nephropathy[J]. Mater Today Bio, 2022, 13, 100181. doi: 10.1016/j.mtbio.2021.100181
53	易聪华, 徐青荷, 王淼, 等. pH敏感性生物基纳米载药粒子的研究进展[J]. 化工进展, 2021, 40 (6): 3411- 3420. doi: 10.16085/j.issn.1000-6613.2020-1423
54	武小东. 多功能载药纳米胶束的结构设计与制备及其在动脉粥样硬化诊疗应用中的研究 [D]. 长春: 吉林大学, 2021.
55	Sullivan HL, Liang Y, Worthington K, et al. Enzyme-responsive nanoparticles for the targeted delivery of an MMP inhibitor to acute myocardial infarction[J]. Biomacromolecules, 2023, 24 (11): 4695- 4704. doi: 10.1021/acs.biomac.3c00421
56	王娜, 杨丽霞. 细胞外基质金属蛋白酶诱导因子与心血管疾病[J]. 国际心血管病杂志, 2024, 51 (6): 356- 359. doi: 10.3969/j.issn.1673-6583.2024.06.008
57	Xiao Z, Li Y, Xiong L, et al. Recent advances in anti-atherosclerosis and potential therapeutic targets for nanomaterial-derived drug formulations[J]. Adv Sci (Weinh), 2023, 10 (29): e2302918. doi: 10.1002/advs.202302918
58	Kumar G, Saini M, Kundu S. Therapeutic enzymes as non-conventional targets in cardiovascular impairments: a comprehensive review[J]. Can J Physiol Pharmacol, 2022, 100 (3): 197- 209. doi: 10.1139/cjpp-2020-0732
59	Liu H, Pietersz G, Peter K, et al. Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis[J]. J Nanobiotechnology, 2022, 20 (1): 75. doi: 10.1186/s12951-022-01279-y
60	Omidian H, Babanejad N, Cubeddu LX. Nanosystems in cardiovascular medicine: advancements, applications, and future perspectives[J]. Pharmaceutics, 2023, 15 (7): 1935. doi: 10.3390/pharmaceutics15071935
61	Zhang Y, Li Y, Huang X, et al. Systemic delivery of siRNA specific for silencing TLR4 gene expression reduces diabetic cardiomyopathy in a mouse model of streptozotocin-induced type 1 diabetes[J]. Diabetes Ther, 2020, 11 (5): 1161- 1173. doi: 10.1007/s13300-020-00802-4
62	熊凌, 郭昆全, 宋文英. AIM2基因沉默对糖尿病大鼠心肌损伤的影响机制[J]. 贵州医科大学学报, 2021, 46 (1): 44- 50.
63	Sundaramoorthy A, Jafar Ali D, Shanmugam N. Inflammatory gene silencing in activated monocytes by a cholesterol tagged-miRNA/siRNA: a novel approach to ameliorate diabetes induced inflammation[J]. Cell Tissue Res, 2022, 389 (2): 219- 240. doi: 10.1007/s00441-022-03637-6
64	Moazzam M, Zhang M, Hussain A, et al. The landscape of nanoparticle-based siRNA delivery and therapeutic development[J]. Mol Ther, 2024, 32 (2): 284- 312. doi: 10.1016/j.ymthe.2024.01.005
65	Pellegrini V, La Grotta R, Carreras F, et al. Inflammatory trajectory of type 2 diabetes: novel opportunities for early and late treatment[J]. Cells, 2024, 13 (19): 1620.
66	Shrivastav D, Singh DD. Emerging roles of microRNAs as diagnostics and potential therapeutic interest in type 2 diabetes mellitus[J]. World J Clin Cases, 2024, 12 (3): 525- 537. doi: 10.12998/wjcc.v12.i3.525
67	Ding Y, Sun X, Shan PF. MicroRNAs and cardiovascular disease in diabetes mellitus[J]. Biomed Res Int, 2017, 2017, 4080364.
68	Das A, Samidurai A, Salloum FN. Deciphering non-coding RNAs in cardiovascular health and disease[J]. Front Cardiovasc Med, 2018, 5, 73. doi: 10.3389/fcvm.2018.00073
69	Szydełko J, Matyjaszek-Matuszek B. MicroRNAs as biomarkers for coronary artery disease related to type 2 diabetes mellitus: from pathogenesis to potential clinical application[J]. Int J Mol Sci, 2022, 24 (1): 562.
70	Dehaini H, Awada H, El-Yazbi A, et al. MicroRNAs as potential pharmaco-targets in ischemia-reperfusion injury compounded by diabetes[J]. Cells, 2019, 8 (2): 152. doi: 10.3390/cells8020152
71	Deng J, Liao Y, Liu J, et al. Research progress on epigenetics of diabetic cardiomyopathy in type 2 diabetes[J]. Front Cell Dev Biol, 2021, 9, 777258. doi: 10.3389/fcell.2021.777258
72	Kankuri E. Positive feedback loop of miR-320 and CD36 regulates the hyperglycemic memory-induced diabetic diastolic cardiac dysfunction[J]. Mol Ther Nucleic Acids, 2023, 32, 318- 321. doi: 10.1016/j.omtn.2023.03.019
73	Tudurachi BS, Anghel L, Tudurachi A, et al. Unraveling the cardiac matrix: from diabetes to heart failure, exploring pathways and potential medications[J]. Biomedicines, 2024, 12 (6): 1250. doi: 10.3390/biomedicines12061314
74	Lezoualc'h F, Badimon L, Baker H, et al. Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality[J]. Cardiovasc Res, 2023, 119 (5): 1130- 1145. doi: 10.1093/cvr/cvac152
75	张笑涵, 刘乃需, 钦扬, 等. 基于整合用药及靶点网络探讨中药治疗2型糖尿病合并高脂血症的核心处方及作用机制[J]. 药物评价研究, 2023, 46 (11): 2309- 2320. doi: 10.7501/j.issn.1674-6376.2023.11.004
76	Tu L, Zou Z, Yang Y, et al. Targeted drug delivery systems for atherosclerosis[J]. J Nanobiotechnology, 2025, 23 (1): 306. doi: 10.1186/s12951-025-03384-0
77	Mimouni M, Lajoix AD, Desmetz C. Experimental models to study endothelial to mesenchymal transition in myocardial fibrosis and cardiovascular diseases[J]. Int J Mol Sci, 2023, 25 (1): 380.

[1]	陈玲, 王中群. 临床研究视角下的SGLT2抑制剂：糖尿病心力衰竭治疗的“破界先锋”[J]. 中国临床药理学与治疗学, 2026, 31(6): 722-728.
[2]	徐晓曼, 周蕾. GLP-1受体激动剂在糖尿病心肌病中的心血管保护作用：机制和临床前景[J]. 中国临床药理学与治疗学, 2026, 31(6): 729-734.
[3]	刘学武, 姜德建, 杜艳华. 糖尿病肾病发病机制及药物研发进展[J]. 中国临床药理学与治疗学, 2026, 31(6): 735-751.
[4]	郭苏, 秦小江, 江雪露, 方梦薇, 满志, 孟欣, 郑志发, 赵良渊, 施熠炜, 侯晓敏. 黄酮类化合物防治糖尿病微血管病变的研究进展[J]. 中国临床药理学与治疗学, 2026, 31(6): 752-763.
[5]	许潇, 王帅霖, 钱欣, 姚逸, 王彰禹, 朱晓奕, 毛庆, 郭齐. 中药治疗糖尿病心肌病研究进展[J]. 中国临床药理学与治疗学, 2026, 31(6): 764-773.
[6]	吴俊, 宋雨薇, 梁宏彪, 冯娟. 氧化三甲胺与糖尿病患者血管重塑[J]. 中国临床药理学与治疗学, 2026, 31(6): 774-781.
[7]	吴瑶, 周旋, 王小燕, 汪带娣, 孙振. 高密度脂蛋白相关比值指数与糖尿病患者冠脉支架植入术后再狭窄发生的关联研究[J]. 中国临床药理学与治疗学, 2026, 31(6): 789-797.
[8]	祁光伟, 仝婉昱, 王冀鲁, 郭靖文, 黎瑞巧, 王启隆. 血栓通对糖尿病内皮细胞线粒体动态平衡、内皮功能损伤和动脉粥样硬化的保护作用研究[J]. 中国临床药理学与治疗学, 2026, 31(6): 798-807.
[9]	周莹, 刘军彤, 王庆峰, 杨宇峰, 石岩. 中药靶向2型糖尿病相关通路的药理机制研究进展[J]. 中国临床药理学与治疗学, 2026, 31(4): 500-508.
[10]	李金菊, 杨浩, 阮诺冰, 许奇, 毕正, 李瑜璠, 王帆竞, 林逸轩, 方朝晖. 糖尿病微血管病变中的细胞衰老及治疗药物研究进展[J]. 中国临床药理学与治疗学, 2026, 31(4): 509-516.
[11]	孙立亚, 李嘉鑫, 孙贵炎, 陈志超, 王庆峰, 杨宇峰, 石岩. 基于肠道菌群和支链氨基酸探讨中医药防治糖尿病肾病的研究进展[J]. 中国临床药理学与治疗学, 2026, 31(4): 527-535.
[12]	吴子瑜, 俞婷, 郑谋炜, 郭太林. 二甲双胍通过上调Nrf2表达抑制糖尿病肾小管上皮细胞铁死亡[J]. 中国临床药理学与治疗学, 2026, 31(1): 40-47.
[13]	刘醒, 陈颖. 2型糖尿病的药物治疗及新技术进展[J]. 中国临床药理学与治疗学, 2025, 30(9): 1215-1223.
[14]	经加吻, 孟庆波, 毕正, 王帆竞, 李瑜璠, 方朝晖. 基于治疗方法的糖尿病勃起功能障碍动物模型研究进展[J]. 中国临床药理学与治疗学, 2025, 30(9): 1224-1232.
[15]	吕程果, 吴采倩, 米芊睿, 张国婧, 李玲, 叶啟发. Apelin：慢性肾脏疾病防治的新靶点[J]. 中国临床药理学与治疗学, 2025, 30(9): 1243-1252.

糖尿病心血管并发症药物分子靶向递送系统的研究进展

Research progress on drug molecular targeted delivery systems for cardiovascular complications of diabetes

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 77

相关文章 15

编辑推荐

Metrics

本文评价